04:21 , Dec 8, 2017 |  BC Week In Review  |  Company News

OncoQuest partners with Tesaro for Phase I/II ovarian cancer combo trial

In October, the OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) partnered with Tesaro Inc. (NASDAQ:TSRO) to conduct a Phase I/II combination trial of OncoQuest's oregovomab (OvaRex Mab, OvaRex) plus Tesaro's Zejula niraparib to treat...
23:32 , Sep 14, 2017 |  BC Week In Review  |  Clinical News

Quest PharmaTech begins Phase I/II of oregovomab for ovarian cancer

The OncoQuest Inc. subsidiary of Quest PharmaTech Inc. (TSX-V:QPT) began a Phase I/II trial of oregovomab (OvaRex Mab, OvaRex) plus Hiltonol (Poly-ICLC) from Oncovir Inc. (Washington, D.C.) to treat recurrent ovarian cancer. The open-label, U.S....
21:01 , May 17, 2017 |  BC Week In Review  |  Clinical News

OncoQuest begins Phase Ib/IIa of oregovomab in ovarian cancer

Quest PharmaTech Inc. (TSX-V:QPT) subsidiary OncoQuest Inc. began the Phase Ib/IIa ORION-01 trial to evaluate oregovomab (OvaRex Mab, OvaRex) plus Opdivo nivolumab in about 32 patients with recurrent epithelial ovarian cancer who have progressed after...
20:43 , Feb 10, 2017 |  BC Week In Review  |  Clinical News

Oregovomab: Interim Ph IIb QPT-ORE-002 data

Quest’s OncoQuest Inc. subsidiary reported interim data from the open-label, U.S. and Italian Phase IIb QPT-ORE-002 trial in 97 patients with newly diagnosed, advanced epithelial ovarian, adnexal or peritoneal carcinoma showing that first-line treatment with...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

Oregovomab: Completed Phase II enrollment

Quest completed enrollment of 80 patients in an open-label, U.S. and Italian Phase IIb trial evaluating 2 mg IV oregovomab plus carboplatin and paclitaxel vs. carboplatin and paclitaxel. Oregovomab is also in Phase II testing...
08:00 , Feb 3, 2014 |  BC Week In Review  |  Company News

Oncovir, Quest Pharma deal

Quest and Oncovir partnered to evaluate Quest's oregovomab in combination with Oncovir's Hiltonol ( Poly-ICLC ) adjuvant in an Italian Phase II trial in 20 patients with ovarian cancer, which is expected to start in...
07:00 , Jul 29, 2013 |  BC Week In Review  |  Company News

AD Biotech, Quest Pharma deal

The companies formed a JV to develop immunotherapies for cancer. The companies will work together to co-develop products that combine their technologies. Quest PharmaTech said the deal gives it access to AD Biotech's antibody, protein...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Clinical News

Ovarex anti-ideotype vaccine data

At the International Society of Oncodevelopmental Biology and Medicine conference in Montreux, Switzerland, AXO presented data from 100 stage III and IV ovarian cancer patients who had taken Ovarex since 1989. Ovarex induced humoral and...
07:00 , Jun 11, 2012 |  BC Week In Review  |  Financial News

Quest Pharma proposes private placement

Quest PharmaTech Inc. (TSX-V:QPT), Edmonton, Alberta   Business: Dermatology, Cancer, Diagnostic   Date announced: 6/5/12   Type: Private placement   To be raised: Up to C$8 million ($7.7 million)   Shares: 15 million   Price...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Company News

Hemispherx, Quest Pharma deal

Quest and Hemispherx partnered to evaluate Quest's cancer candidate oregovomab with Hemispherx's Ampligen rintatolimod to treat advanced ovarian cancer in a Phase I/II trial. The partners will equally split the $1 million cost of the...